Clinical Pharmacologist, Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy.
Hospital Pharmacist Manager, Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy.
Inflammopharmacology. 2021 Jun;29(3):645-649. doi: 10.1007/s10787-021-00811-0. Epub 2021 May 1.
The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a percentage of cases can be fatal. Recently, the first COVID-19 vaccines have been authorised, starting a massive vaccination campaign worldwide. The COVID-19 vaccines authorized or under testing use different methods of action such as mRNA, DNA vaccine, viral vector, protein subunit, and virus inactivated immunization strategies. The mRNA vaccines are the first authorised vaccines with this new method of action, initiating a new era of preventive medicine. To date, data indicate that they may be effective against the newly identified SARS-CoV-2 variants. Short-term studies indicated an acceptable safety profile but long-term immunity as well as safety is not yet available. In this article, we briefly describe mRNA vaccines and highlight some aspects yet to be fully defined.
全球 COVID-19 大流行仍在全球范围内造成人员伤亡，这是人类历史上前所未有的健康和社会经济挑战。用于治疗 COVID-19 感染的治疗药物主要旨在避免最严重的并发症和器官损伤，在某些情况下，这些并发症和器官损伤可能是致命的。最近，第一批 COVID-19 疫苗已获得授权，全球范围内开始了大规模的疫苗接种运动。已授权或正在测试的 COVID-19 疫苗使用不同的作用方式，如 mRNA、DNA 疫苗、病毒载体、蛋白亚单位和病毒灭活免疫策略。mRNA 疫苗是首批采用这种新作用方式的授权疫苗，开创了预防医学的新纪元。迄今为止，数据表明它们可能对新发现的 SARS-CoV-2 变体有效。短期研究表明安全性良好，但长期免疫和安全性尚不清楚。在本文中，我们简要描述了 mRNA 疫苗，并强调了一些尚未完全确定的方面。
